Vigonvita Life Sciences Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Suzhou Vigonvita Life Sciences Co., Ltd. (to 2026)
1
Ending by 2030
Jul 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 5, 2027The maintenance fee for Antiviral Application of Nucleoside Analog or Combination Formulation Containing Nucleoside Analog (US 11,919,923) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,871,777 | Phenylpyrimidone Compounds, the Pharmaceutical Compositions, Preparation Methods and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,434,226 | Salt and Polymorph of Benzopyrimidinone Compound and Pharmaceutical Composition and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,384,073 | Maleate Salt of Benzothiophene Compound, Crystalline Form Thereof, and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,919,923 | Antiviral Application of Nucleoside Analog or Combination Formulation Containing Nucleoside Analog In force · High confidence | In force | High confidence | |
| US 12,351,599 | Antiviral Application of Nucleoside Analog or Combination Formulation Containing Nucleoside Analog In force · Low confidence | In force | Low confidence | |
| US 12,780,825 | Salt of Nucleoside Analog, and Crystal Form, Pharmaceutical Composition and Use Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 6: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending